Mercer Global Advisors
BBIO icon

Mercer Global Advisors’s BridgeBio Pharma BBIO Stock Holding History

Mercer Global Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,198
Closed -$360K – 1961
2024
Q2 		$360K Sell
14,198
-73
-0.5% -$2K ﹤0.01% 1488
2024
Q1 		$441K Buy
14,271
+99
+0.7% +$3.37K ﹤0.01% 1346
2023
Q4 		$572K Buy
14,172
+59
+0.4% +$1.77K ﹤0.01% 1238
2023
Q3 		$372K Hold
14,113
– – ﹤0.01% 1404
2023
Q2 		$243K Buy
14,113
+3,613
+34% +$54.4K ﹤0.01% 1633
2023
Q1 		$174K Sell
10,500
-39
-0.4% -$455 ﹤0.01% 1757
2022
Q4 		$80K Hold
10,539
– – ﹤0.01% 1838
2022
Q3 		$105K Buy
+10,539
New +$109K ﹤0.01% 1713

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mercer Global Advisors's BBIO Position: Q3 2024 in Review

Mercer Global Advisors sold out of BridgeBio Pharma (BBIO) in Q3 2024, closing a stake of 14,198 shares — an estimated $360K sold.

Mercer Global Advisors first reported a position in BBIO in Q3 2022 and held it in 8 quarters. The position peaked at $572K in Q4 2023. 253 funds tracked by Wall St. Rank hold BBIO as of Q3 2024.

  • Mercer Global Advisors reported no remaining BridgeBio Pharma position as of Q3 2024 after selling out during the quarter.
  • Mercer Global Advisors sold 14,198 BridgeBio Pharma shares in Q3 2024, an estimated $360K.
  • Mercer Global Advisors first reported a position in BridgeBio Pharma in Q3 2022 and held it in 8 quarters.
  • Mercer Global Advisors's BridgeBio Pharma position peaked at $572K in Q4 2023.
  • 253 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2024.

Based on Mercer Global Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.